Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
VAP-1(Amine oxidase, copper containing) | 1 |
CXCR4(C-X-C motif chemokine receptor 4) | 1 |
Target |
Mechanism 5-HT1A receptor agonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism VAP-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CXCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
USL-311 ( CXCR4 ) | Glioblastoma More | Phase 2 Clinical |
PRX-167700 ( VAP-1 ) | Pain More | Phase 2 |
GW-876167 ( 5-HT2C receptor ) | Obesity More | Discontinued |
Naluzotan Hydrochloride ( 5-HT1A receptor ) | Dyskinesia, Drug-Induced More | Discontinued |
Sabcomeline Hydrochloride ( M1AChR ) | Alzheimer Disease More | Discontinued |